1st Oct 2009 08:58
Thursday 1 October 2009
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Directors' Holdings
Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that, further to an announcement dated 25 September 2009, the 16,273,393 ordinary shares issued to Azure Ventures Limited, pursuant to a partial exercise of a warrant on 24 September 2009 have been admitted to trading on AIM.
Azure Ventures Limited is now interested in 132,940,059 shares, representing 45.41 per cent. of the Company's total voting rights.
Alejandro Weinstein, a non-executive director of the Company, is one of the ultimate beneficiaries under the Karjiang Pharma Trust which is the sole shareholder of Azure Ventures Limited.
The Company's issued share capital consists of 292,771,944 ordinary shares.
For further information
|
Allergy Therapeutics |
+44 (0) 1903 845 820 |
|
Ian Postlethwaite, Finance Director |
|
|
www.allergytherapeutics.com |
|
|
Nomura Code Securities |
+44 (0) 207 776 1200 |
|
Juliet Thompson/ Clare Terlouw |
|
|
Financial Dynamics |
+44 (0) 207 831 3113 |
|
Ben Brewerton/ Susan Quigley |
Related Shares:
Allergy Thera.